K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 376 JPY 0.3% Market Closed
Market Cap: 165.7B JPY
Have any thoughts about
Kaken Pharmaceutical Co Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Kaken Pharmaceutical Co Ltd stock under the Base Case scenario is 2 056.67 JPY. Compared to the current market price of 4 376 JPY, Kaken Pharmaceutical Co Ltd is Overvalued by 53%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
2 056.67 JPY
Overvaluation 53%
Relative Value
Price
K
Worst Case
Base Case
Best Case

Valuation Multiples

2.3
P/S
P/S
Price to Sales
2.3
vs History
30
vs Industry
51
Median 3Y
1.9
Median 5Y
1.9
Industry
2.6
Forward
2
More Details
22.8
P/E
P/E
Price to Earnings
22.8
vs History
23
vs Industry
25
Median 3Y
16.9
Median 5Y
14.9
Industry
23
Forward
12.2
More Details
64.3
P/OCF
P/OCF
Price to OCF
64.3
vs History
4
vs Industry
6
Median 3Y
14.4
Median 5Y
11
Industry
17.8
More Details
418.7
P/FCFE
P/FCFE
Price to FCFE
418.7
vs History
4
vs Industry
1
Median 3Y
19
Median 5Y
14
Industry
25.4
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
60
vs Industry
59
Median 3Y
1
Median 5Y
1
Industry
2.2
More Details
1.4
EV/S
EV/S
Enterprise Value to Sales
1.4
vs History
31
vs Industry
65
Median 3Y
1
Median 5Y
1
Industry
2.8
Forward
1.2
More Details
2.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.7
vs History
25
vs Industry
67
Median 3Y
1.8
Median 5Y
1.9
Industry
5.4
More Details
8.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.8
vs History
14
vs Industry
39
Median 3Y
5.7
Median 5Y
4.6
Industry
13.7
Forward
4.8
More Details
11.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.5
vs History
14
vs Industry
37
Median 3Y
7.4
Median 5Y
5.1
Industry
17.2
More Details
40
EV/OCF
EV/OCF
Enterprise Value to OCF
40
vs History
4
vs Industry
12
Median 3Y
7.1
Median 5Y
5.6
Industry
16.5
More Details
251.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
251.2
vs History
4
vs Industry
2
Median 3Y
9.4
Median 5Y
7.2
Industry
19.3
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
60
vs Industry
60
Median 3Y
0.8
Median 5Y
0.9
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
Kaken Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Kaken Pharmaceutical Co Ltd
TSE:4521
165.7B JPY 2.3 22.8 8.8 11.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.5B USD 18.5 90.4 48.6 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
364.1B USD 4.2 24.8 12 15.6
US
Merck & Co Inc
NYSE:MRK
248.4B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.5B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.2B CHF 4.2 12.6 10 14.9
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.5 169.4 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
JP
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Average P/E: 32
22.8
-94%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.8
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 198,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.